Nephrology and Hypertension

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. Monogenic Kidney Stone - Genetic Testing

   Rochester, Minn.

   90 genes related to Monogenic Stone Disease will be determined via DNA analysis by the Mayo Rare Kidney Stone Consortium (RKSC) research staff.

2. A Study to Determine the Incidence of Atrial and Ventricular Arrhythmias in Patients with Hypertrophic Cardiomyopathy

   Rochester, Minn.

   The purpose of this study is to determine the incidence of atrial and ventricular arrhythmias in patients with hypertrophic cardiomyopathy, with and without sleep apnea.

3. Acute Kidney Injury in Care Transitions (ACT) Trial

   Rochester, Minn.

   The purpose of this study is to evaluate the feasibility and acceptability of the AKI in Care Transitions pilot and iteratively refine the intervention.  Generate preliminary estimates of the ACT intervention on clinical and patient-reported outcomes.

4. A Study to Evaluate the Effectiveness and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients

   Rochester, Minn.

   The purpose of this study is to investigate how efficiently the study medication imlifidase reduces the amount of donor specific antibodies (DSA) in comparison with plasma exchange (PE) therapy, in patients who have an active antibody mediated rejection (AMR) after recently been kidney transplanted. The purpose is also to investigate and compare safety for these two treatments. 20 patients will be treated with imlifidase and 10 with PE.

5. A Study to Predict Sepsis-Associated Acute Kidney Injury by Assessing Renal Microvascular Blood Flow and Elasticity with Contrast-Enhanced Ultrasonography and Ultrasound Elastogram

   Rochester, Minn.

   The purpose of this study is to assess kidney microcirculation using contrast-enhanced ultrasonography associated with kidney ultrasound elastography among patients who are at risk of sepsis-associated acute kidney injury provides strong predictive ability for AKI and potential therapeutic targets. 

    

6. Baxdrostat in Uncontrolled Hypertension on Two or More Medications Including Resistant Hypertension

   Rochester, Minn., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally, on the reduction of systolic blood pressure in approximately 720 participants aged ≥ 18 years with hypertension, despite a stable regimen of 2 antihypertensive agents at baseline, one of which is a diuretic (uncontrolled hypertension); or ≥ 3 antihypertensive agents at baseline, one of which is a diuretic (treatment-resistant hypertension).